Signal peptide-binding drug as a selective inhibitor of co-translational protein translocation

• Published in: PLoS biology 2014-12, Vol.12 (12), p.e1002011
• Main Authors: Vermeire, Kurt, Bell, Thomas W, Van Puyenbroeck, Victor, Giraut, Anne, Noppen, Sam, Liekens, Sandra, Schols, Dominique, Hartmann, Enno, Kalies, Kai-Uwe, Marsh, Mark
• Format: Article
• Language: English
• Subjects: Amino Acid Sequence; Biology and Life Sciences; CD4 Antigens - chemistry; CD4 Antigens - metabolism; Down-Regulation - drug effects; Drug interactions; Endoplasmic reticulum; Health aspects; HIV; Human immunodeficiency virus; Humans; Hydrophobic and Hydrophilic Interactions; Infections; Laboratories; Medical research; Molecular Sequence Data; Peptides; Pharmaceutical research; Protein Biosynthesis - drug effects; Protein Conformation; Protein research; Protein Sorting Signals; Protein Synthesis Inhibitors - pharmacology; Protein Transport - drug effects; Proteins; Sulfonamides - chemistry; Sulfonamides - pharmacology; Translocation (Genetics)
• ISSN: 1545-7885; 1544-9173; 1545-7885
• DOI: 10.1371/journal.pbio.1002011

In eukaryotic cells, surface expression of most type I transmembrane proteins requires translation and simultaneous insertion of the precursor protein into the endoplasmic reticulum (ER) membrane for subsequent routing to the cell surface. This co-translational translocation pathway is initiated when a hydrophobic N-terminal signal peptide (SP) on the nascent protein emerges from the ribosome, binds the cytosolic signal recognition particle (SRP), and targets the ribosome-nascent chain complex to the Sec61 translocon, a universally conserved protein-conducting channel in the ER-membrane. Despite their common function in Sec61 targeting and ER translocation, SPs have diverse but unique primary sequences. Thus, drugs that recognise SPs could be exploited to inhibit translocation of specific proteins into the ER. Here, through flow cytometric analysis the small-molecule macrocycle cyclotriazadisulfonamide (CADA) is identified as a highly selective human CD4 (hCD4) down-modulator. We show that CADA inhibits CD4 biogenesis and that this is due to its ability to inhibit co-translational translocation of CD4 into the lumen of the ER, both in cells as in a cell-free in vitro translation/translocation system. The activity of CADA maps to the cleavable N-terminal SP of hCD4. Moreover, through surface plasmon resonance analysis we were able to show direct binding of CADA to the SP of hCD4 and identify this SP as the target of our drug. Furthermore, CADA locks the SP in the translocon during a post-targeting step, possibly in a folded state, and prevents the translocation of the associated protein into the ER lumen. Instead, the precursor protein is routed to the cytosol for degradation. These findings demonstrate that a synthetic, cell-permeable small-molecule can be developed as a SP-binding drug to selectively inhibit protein translocation and to reversibly regulate the expression of specific target proteins.